Answers are grounded in this paper and cite their sources.
Objective To characterize the severity, progression, chronicity and treatment of ICI-induced N-Tox in a standard of care (SOC) setting. Background ICI-induced N-Tox is understudied despite its morbidity and potential mortality. Our previous report on melanoma patients enrolled in ICI phase III clinical trials revealed that 32% of patients with mild/non-specific symptoms progressed to more severe N-Tox, and in some cases required hospitalization. However, the management information of N-Tox and long-term outcomes were unavailable, and the high rate of progression has not previously been studied in SOC setting. Design/Methods We conducted a single institution study of melanoma patients enrolled in a prospective database who received ICI as SOC and developed N-Tox. We analyzed their clinical manifestations, treatment outcomes, laboratory, neuroimaging, and electrophysiologic data. Results 89/666 (13%) patients developed N-Tox (G1:33, G2:31, G3:18, G4:4) ranging from 2% with ipilimumab, 5% with nivolumab+relatlimab, 9% with pembrolizumab, 14% with nivolumab, and 15% with ipilimumab+nivolumab. Peripheral neuropathy and myopathy were the most common N-Tox. 49(55%) patients initially presented with mild non-specific neurological symptoms and 27(30%) progressed to more severe N-Tox. 46(51%) required ICI discontinuation or interruption and 20(22%) were hospitalized. 38(43%) patients received corticosteroids and 5(6%) required IVIG, PLEX, or rituximab. Median time to N-Tox resolution was 53 days, however, 30(33%) patients had persistent symptoms >3 months. Grade≥2 N-Tox was significantly associated with chronicity ( p =0.02, OR=2.98). Among N-Tox patients with available laboratory results, 24/31(77%) had elevated ESR, 22/36(61%) had elevated CRP, 6/12(50%) had elevated ANA, 8/8(100%) had elevated CSF protein and glucose; EMGs for patients with peripheral neuropathy showed axonal (4/11), demyelinating (1/11), and mixed neuropathy (3/11). Conclusions Our data demonstrate frequent progression of mild/nonspecific symptoms to more severe N-Tox, leading to treatment disruptions, hospitalization and substantial chronicity. Thus, early identification and management of N-Tox in ICI-treated patients, and the need for standardized management in the prospective setting is crucial.
No takes yet. Share an insight, caveat, or question.
Dutt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: